
    
      This first-in-human (FIH) clinical study is a Phase 1, randomised, double-blind,
      placebo-controlled study to assess the safety, tolerability, and PK of NaQuinate in healthy
      subjects after single ascending oral (PO) doses and multiple ascending PO doses.
    
  